You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

Bulk Pharmaceutical API Sources for DEXTROSE 40% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for DEXTROSE 40% IN PLASTIC CONTAINER

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Start Trial 66370 ⤷  Start Trial
IS Chemical Technology ⤷  Start Trial I14-6963 ⤷  Start Trial
ABI Chem ⤷  Start Trial AC1L2586 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS015915125 ⤷  Start Trial
Chembase.cn ⤷  Start Trial 106156 ⤷  Start Trial
ChemMol ⤷  Start Trial 99098420 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Dextrose 40% in Plastic Container

Last updated: September 6, 2025

Introduction

Dextrose 40% in plastic containers is a sterile, high-concentration glucose solution widely used in medical settings, including parenteral nutrition and infusion therapy. As a critical component in clinical care, ensuring a reliable supply chain of pharmaceutical-grade dextrose API is paramount. This article examines the key sources for bulk dextrose API suitable for manufacturing Dextrose 40%, focusing on global producers, quality standards, regulatory considerations, and supply chain dynamics.

Understanding Dextrose API and Its Significance

Dextrose, chemically known as D-glucose, is a monosaccharide with extensive applications in the pharmaceutical and food industries. Its pharmaceutical-grade API is produced through rigorous manufacturing processes to meet standards like the FDA’s Current Good Manufacturing Practices (cGMP), USP (United States Pharmacopeia), and EP (European Pharmacopoeia) specifications. The API's grade directly influences the safety, efficacy, and quality of end-use products like Dextrose 40% solutions.

High-quality dextrose API ensures the stability, sterility, and compatibility necessary for sterile preparations. Its source selection influences the overall quality of the infusion solutions, patient safety, and regulatory compliance.

Major Global API Suppliers for Dextrose

1. Cargill, Incorporated

Overview: Cargill is among the world's largest producers of dextrose API, with extensive manufacturing facilities in North America, Europe, and Asia. Cargill’s dextrose is derived from corn starch through enzymatic hydrolysis, ensuring high purity and compliance with pharmacopeial standards.

Quality & Certification: Cargill’s pharmaceutical-grade dextrose API meets USP, EP, and JP standards. The company maintains strict quality control, including endotoxin testing, microbiological standards, and batch-to-batch consistency.

Supply Capabilities: Capable of large-volume API supply, Cargill offers custom grades and packaging solutions suited for infusion preparations. Their API is suitable for pharmaceutical formulations requiring sterile processing, including manufacturing Dextrose 40%.

Regulatory Compliance: Cargill complies with global regulations, including FDA registration, ISO certifications, and cGMP standards.

2. Archer Daniels Midland Company (ADM)

Overview: ADM is a leading producer of dextrose API, leveraging advanced enzymatic conversion techniques from maize starch. Their facilities are strategically located across North America, Europe, and Asia.

Quality & Certification: ADM’s pharmaceutical dextrose API adheres to USP and EP monographs, with extensive testing for contaminants, endotoxins, and microbiological safety. Their certifications include ISO 9001 and cGMP compliance.

Supply Capabilities: ADM supplies bulk dextrose API in various grades suitable for sterile injections, with robust quality assurance protocols. They offer customization in packaging, including bulk drums and customized containers.

Regulatory Standing: The company maintains extensive dossier data for regulatory agencies, supporting compliance in different regions.

3. Roquette Frères

Overview: A global leader in plant-based ingredients, Roquette supplies pharmaceutical-grade dextrose API from their operations in Europe and North America. Their API is sourced from certified corn starch.

Quality & Certification: Roquette’s dextrose API meets pharmacopeial standards, including USP and EP, with an emphasis on purity, endotoxin/IP standards, and microbiological safety.

Supply Chain & Capacity: Their extensive manufacturing infrastructure allows reliable large-scale API production, with supply chains optimized for global distribution.

Special Highlights: Roquette emphasizes sustainable sourcing and environmentally friendly manufacturing practices, aligning with regulatory and corporate sustainability goals.

4.经营/海外制造商(Chinese and Indian API producers)

Overview: A significant portion of bulk dextrose API is sourced from Chinese and Indian manufacturers due to cost advantages and competitive pricing. Reputable suppliers include Shandong Xinhua Pharmaceutical and Venkatesh Pharmachem from India.

Quality & Certification: Not all suppliers meet international pharmacopeial standards. However, leading manufacturers export API that complies with USP, EP, and BP specifications, often supported by third-party testing and certifications.

Considerations: Procurement from these sources requires rigorous qualification processes, including auditing, quality audits, and qualification of supply chain reliability. Regulatory acceptance varies; some markets may have restrictions on imported raw materials, necessitating prior assessment.

5. Domestic (Regional) API Suppliers

In regions like Europe, North America, and Australia, several domestic suppliers provide pharmaceutical-grade dextrose API. These suppliers often have closer regulatory oversight and shorter lead times, appealing for high-precision manufacturing.


Regulatory and Quality Considerations

When sourcing dextrose API, manufacturers must prioritize suppliers' adherence to stringent quality standards, including:

  • cGMP compliance
  • Pharmacopoeial adherence (USP, EP, JP)
  • Endotoxin levels and microbiological purity
  • Stability and certification of raw materials

Regulatory authorities scrutinize raw material sourcing, emphasizing traceability, validation, and supplier qualification.


Supply Chain Dynamics

The stability of API supply chains influences formulation availability, especially for high-demand products like Dextrose 40%. Disruptions may result from geopolitical tensions, pandemics, or natural disasters. Leading suppliers with diversified manufacturing sites mitigate such risks, ensuring uninterrupted supply. Contract manufacturing organizations (CMOs) can also supplement supply, provided they adhere to regulatory compliance and quality assurance protocols.


Market Trends and Future Outlook

The global demand for sterile, high-concentration glucose solutions is expected to grow, driven by an aging population and expanding healthcare infrastructure. API sourcing strategies are shifting toward greater reliance on API integrators with robust quality management systems. Advances in synthetic and biotechnological processes hold promise for more sustainable and cost-effective API production, potentially impacting available sources.


Key Takeaways

  • Major suppliers like Cargill, ADM, and Roquette dominate the global API market for pharmaceutical dextrose, offering high-quality, pharmacopeial-grade API suitable for sterile formulations.
  • Sourcing from reputable manufacturers with transparent quality certifications (USP, EP, cGMP) ensures product safety and regulatory compliance.
  • Chinese and Indian suppliers can provide cost-effective API options, but require thorough qualification and validation due to variable quality standards.
  • Supply chain resilience is critical for consistent production; diversified sourcing mitigates risks associated with geopolitical and logistical disruptions.
  • Emerging biotech methods and sustainability initiatives are influencing future API production, with potential for more ethical and stable supply options.

FAQs

1. What are the key quality standards for pharmaceutical-grade dextrose API?
Pharmaceutical-grade dextrose API must meet pharmacopeial standards such as USP, EP, or JP, which specify purity, endotoxin levels, microbiological safety, and stability.

2. Can dextrose API from Chinese or Indian manufacturers be reliably used for sterile Dextrose 40% solutions?
Yes, but procurement requires thorough qualification, validation, and verification of certifications to ensure compliance with international quality standards.

3. How does the choice of API source affect the stability of Dextrose 40% infusions?
High-quality API ensures batch-to-batch consistency and purity, reducing risks of contamination or instability in sterile solutions.

4. Are there regulatory restrictions on sourcing dextrose API from certain regions?
Some markets may restrict or closely scrutinize imports from specific regions, requiring detailed documentation and quality assurance, especially for sterile pharmaceutical applications.

5. What trends are shaping the future of dextrose API supply for pharmaceutical use?
Increased demand for sustainable production, biotechnological innovations, and supply chain diversification are key trends influencing API sourcing strategies.


References

  1. Cargill, Inc. Pharmaceutical-grade Dextrose products
  2. ADM: Dextrose API specifications and quality standards
  3. Roquette Frères: Pharma-grade Dextrose solutions
  4. US Pharmacopeia (USP) Monograph for Dextrose, USP Dictionary, 2022.
  5. European Pharmacopoeia (EP) Monographs for Dextrose, EP 9th Edition.

Disclaimer: This article is for informational purposes and should be supplemented with direct supplier consultations and regulatory guidance to ensure compliance with regional requirements.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.